Miami, FL (May 25th, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company will be presenting at the annual meeting of the International Society of Cell and Gene Therapy (ISCT) taking place on May 26-28, 2021.
Organicell’s work, which was selected for an oral presentation, will be part of a session titled: “EVs for Infectious Diseases and Preparedness for Future Pandemics – ISCT-ISEV Joint Session” and is scheduled to be broadcast live to program registrants on May 27th.
This presentation comes as a follow up to recently published case report studies demonstrating the investigation of Zofin™ in three severely ill COVID-19 patients. In these studies, results found the administration of Zofin™ to be associated with decreased levels of inflammatory biomarkers, such as CRP and IL6.
COVID-19 infection complications are, in part, the result of an excessive immune response with the over-production of pro-inflammatory cytokines such as IL6 and CRP. Therefore, the observation of reduced concentration of these biomarkers may indicate a positive trend towards recovery.
ISCT is the global steward fostering cell and gene therapy translation to the clinic. With a network of leading clinicians, regulators, researchers, technologists and industry partners, ISCT members have a shared vision to translate cell and gene therapies into safe and effective therapies to improve patients’ lives worldwide. For more information about the organization, please visit: isctglobal.org.
“We are excited that our work was selected amongst other researchers investigating the therapeutic potential of extracellular vesicles for infectious disease of future pandemics,” said Mari Mitrani, M.D., Ph.D., Chief Science Officer of Organicell.
About Zofin™
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.